QBiotics board changes
BRISBANE, 19 November 2024
QBiotics Group Limited (QBiotics) announces that, following a long and productive tenure, Professor Bruce Robinson AC and Mr Andrew Denver will retire from the Board of Directors following the Company’s Annual General Meeting of shareholders on Friday, 22 November 2024.
Along with the recent appointment of new directors, Mark Fladrich and David Phillips and CEO and Managing Director, Stephen Doyle, these changes align with the board renewal strategy initiated last year.
Non-Executive Chairman, Mark Fladrich commented, “Andy and Bruce have served on the QBiotics Board in a variety of roles since 2016. We extend our gratitude and our thanks to Bruce and Andy for their contributions, commitment and service. We wish them all the very best for the future.”
Prof Bruce Robinson AC and Mr Andrew Denver both joined the Board of QBiotics Group on 1 November 2017, after having initially being appointed to the board of predecessor company QBiotics Limited on 1 June 2016.
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com or
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013 is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.